Side-by-side · Research reference

ChonlutenvsTB-500

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED8/38 cited

BPhase 2HUMAN-REVIEWED8/46 cited

Chonluten

Khavinson Bioregulator · Bronchial Mucosa

BronchialTarget tissue

In vitroEvidence tierAvolio 2022

THP-1Model systemAvolio 2022

Oral · Sublingual · Per Protocol

TB-500

Thymosin β4 fragment · Healing

2 mgPer doseGoldstein 2012

Phase 2Evidence levelGoldstein 2012

~2 hrHalf-life

SQ or IM · Multiple sites · 2–3×/week

01Mechanism of Action

Parameter

Chonluten

TB-500

Primary target

Bronchial epithelial cells and respiratory mucosa tissue complexes

G-actin (sequestering) + cell-surface integrinsGoldstein 2012

Pathway

Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022

Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012 Malinda 1999

Downstream effect

Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022

Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012

Feedback intact?

—

Endogenous protein at baseline; supplementation amplifies

Origin

Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology

17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012

Antibody development

—

02Dosage Protocols

Parameter

Chonluten

TB-500

Typical protocol dose

10–20 mg / day

Russian bioregulator tradition dosing; not standardized in Western literature.

—

Frequency

Once or twice daily

2× per week (loading); then 1× per week (maintenance)

Route

Oral (capsule) or sublingual

Sublingual claimed for enhanced bioavailability; not validated.

—

Evidence basis

In vitro mechanistic

Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012

Duration

10–30 days per cycle

Traditional Khavinson protocol; cyclic administration common.

4–8 weeks loading; longer maintenance for chronic injury

Clinical validation

None (PubMed indexed)

—

Standard dose

—

2 mg per injectionGoldstein 2012

Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.

Lower / starter dose

—

1 mg per injection

Reconstitution

—

Bacteriostatic water, 1–2 mL per 5 mg vial

Timing

—

Evening or pre-rest preferred (anecdotal)

Half-life

—

~2 hours (estimated; tissue uptake longer)

04Side Effects & Safety

Parameter

Chonluten

TB-500

Documented adverse events

No published safety data in PubMed-indexed literature

—

Theoretical risks

Peptide hypersensitivity, GI intolerance (uncharacterized)

—

Drug interactions

Unknown — no pharmacokinetic studies available

—

Pregnancy / lactation

No data — avoid

—

Injection site reaction

—

Mild erythema, transient pain

GI symptoms

—

Rare nausea (anecdotal)

Cancer risk

—

Theoretical via angiogenesis pathway

Lethargy / fatigue

—

Reported anecdotally during loading phase

Antibody formation

—

No data (no long-term human trials)

Pregnancy / OB

—

Avoid

Long-term safety

—

Unknown beyond Phase 2

Absolute Contraindications

Chonluten

·Known hypersensitivity to peptide components

TB-500

·Active malignancy (theoretical angiogenesis concern)
·Pregnancy / breastfeeding

Relative Contraindications

Chonluten

·Pregnancy and lactation (insufficient data)
·Active malignancy (theoretical bioregulator concern)

TB-500

·Cancer history
·Concurrent VEGF inhibitor therapy

05Administration Protocol

Parameter

Chonluten

TB-500

1. Preparation

Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.

Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.

2. Oral route

Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.

SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.

3. Sublingual route

Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.

Evening or pre-sleep is most common anecdotal timing.

4. Timing

Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

5. Cycle protocol

10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.

27–31G, 4–8 mm insulin syringe.

06Stack Synergy

Chonluten

— no documented stacks

TB-500

+ BPC-157

Strong

View BPC-157 →

TB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.

TB-500: 2 mg SQ · 2× per week
BPC-157: 250–500 mcg SQ · daily
Primary benefit: Combined angiogenesis + cell migration for tendon/ligament/muscle repair